Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.

The COVID-19 pandemic had a profound impact on global health, but rapid vaccine administration resulted in a significant decline in morbidity and mortality rates worldwide. In this study, we sought to explore the temporal changes in the humoral immune response against SARS-CoV-2 healthcare workers (HCWs) in Augusta, GA, USA, and investigate any potential associations with ethno-demographic features. Specifically, we aimed to compare the naturally infected individuals with naïve individuals to understand the immune response dynamics after SARS-CoV-2 vaccination. A total of 290 HCWs were included and assessed prospectively in this study. COVID status was determined using a saliva-based COVID assay. Neutralizing antibody (NAb) levels were quantified using a chemiluminescent immunoassay system, and IgG levels were measured using an enzyme-linked immunosorbent assay method. We examined the changes in antibody levels among participants using different statistical tests including logistic regression and multiple correspondence analysis. Our findings revealed a significant decline in NAb and IgG levels at 8-12 months postvaccination. Furthermore, a multivariable analysis indicated that this decline was more pronounced in White HCWs (odds ratio [OR] = 2.1, 95% confidence interval [CI] = 1.07-4.08, p = 0.02) and IgG (OR = 2.07, 95% CI = 1.04-4.11, p = 0.03) among the whole cohort. Booster doses significantly increased IgG and NAb levels, while a decline in antibody levels was observed in participants without booster doses at 12 months postvaccination. Our results highlight the importance of understanding the dynamics of immune response and the potential influence of demographic factors on waning immunity to SARS-CoV-2. In addition, our findings emphasize the value of booster doses to ensure durable immunity.

[1]  D. Contopoulos-Ioannidis,et al.  Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis , 2023, International Journal of Infectious Diseases.

[2]  Jin Zhang,et al.  Immunology of SARS-CoV-2 infection and vaccination , 2023, Clinica chimica acta; international journal of clinical chemistry.

[3]  J. Fantini,et al.  Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies , 2023, Pathogens.

[4]  C. Heaney,et al.  SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022 , 2023, mSphere.

[5]  Zahra A. Premji,et al.  Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression , 2023, The Lancet Infectious Diseases.

[6]  M. Weekes,et al.  Demographic, behavioural and occupational risk factors associated with SARS-CoV-2 infection in UK healthcare workers: a retrospective observational study , 2022, BMJ Open.

[7]  A. Ghaemmaghami,et al.  Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals , 2022, Scientific Reports.

[8]  J. Gonzalez,et al.  Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations , 2022, Viruses.

[9]  David A. Jolliffe,et al.  Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK) , 2022, Vaccines.

[10]  T. Zewotir,et al.  Identifying Potential Factors Associated with High HIV viral load in KwaZulu-Natal, South Africa using Multiple Correspondence Analysis and Random Forest Analysis , 2022, BMC Medical Research Methodology.

[11]  E. Boerwinkle,et al.  Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey , 2022, The Journal of infectious diseases.

[12]  P. Bochud,et al.  Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19 , 2022, Viruses.

[13]  D. McGovern,et al.  Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis , 2022, BMJ Open.

[14]  Wan-zhou Xu,et al.  Dynamic changes of serum SARS-CoV-2 antibody levels in COVID-19 patients , 2022, Journal of Infection.

[15]  J. Lambert,et al.  Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms , 2022, Open forum infectious diseases.

[16]  V. Calvez,et al.  Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation , 2022, Frontiers in Immunology.

[17]  S. Haslett,et al.  Creating symptom-based criteria for diagnostic testing: a case study based on a multivariate analysis of data collected during the first wave of the COVID-19 pandemic in New Zealand , 2021, BMC Infectious Diseases.

[18]  E. Kabagambe,et al.  Prevalence, Distribution and IgG Antibody Levels Associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Health-System and Community-Based Employees and Patients , 2021, The American Journal of the Medical Sciences.

[19]  M. Secrest,et al.  Factors associated with COVID-19 viral and antibody test positivity and assessment of test concordance: a retrospective cohort study using electronic health records from the USA , 2021, BMJ Open.

[20]  G. Gao,et al.  Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021 , 2021, International immunology.

[21]  D. Wang,et al.  Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice , 2021, Military Medical Research.

[22]  J. Tanne Covid-19: FDA approves Pfizer-BioNTech vaccine in record time , 2021, BMJ.

[23]  A. Walker,et al.  Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, medRxiv.

[24]  Eleanor L. Ross,et al.  An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  C. Knabbe,et al.  SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study , 2021, Vaccine.

[26]  Tangchun Wu,et al.  Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection , 2021, Cellular & Molecular Immunology.

[27]  C. Di Resta,et al.  Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects , 2021, Vaccine.

[28]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[29]  D. Altmann,et al.  Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 , 2021, npj Vaccines.

[30]  M. Hegde,et al.  Clinical Validation of a Sensitive Test for Saliva Collected in Healthcare and Community Settings with Pooling Utility for Severe Acute Respiratory Syndrome Coronavirus 2 Mass Surveillance , 2021, The Journal of Molecular Diagnostics.

[31]  Mark Hopkins,et al.  Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK , 2021, Frontiers in Medicine.

[32]  G. Wogan,et al.  Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset , 2021, Proceedings of the National Academy of Sciences.

[33]  G. Rodger,et al.  The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[34]  G. Gao,et al.  Viral targets for vaccines against COVID-19 , 2020, Nature reviews. Immunology.

[35]  K. Stirrups,et al.  A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital , 2020, Journal of Infection.

[36]  M. Blaser,et al.  Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospital Workers: Results From a Screening Study in New Jersey, United States in Spring 2020 , 2020, Open forum infectious diseases.

[37]  S. Ciesek,et al.  Analysis of humoral immune responses in SARS-CoV-2 infected patients , 2020, The Journal of infectious diseases.

[38]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[39]  Lars G. Fritsche,et al.  Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System , 2020, JAMA network open.

[40]  G. Chertow,et al.  Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study , 2020, The Lancet.

[41]  M. Veldhoen,et al.  Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset , 2020, medRxiv.

[42]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[43]  C. Hillyer,et al.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.

[44]  Yaokai Chen,et al.  Patterns of IgG and IgM antibody response in COVID-19 patients , 2020, Emerging microbes & infections.

[45]  P. Neven,et al.  Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy , 2019, Breast Cancer Research and Treatment.

[46]  M. Mottolese,et al.  A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study , 2008, Breast Cancer Research.